Technical analysis : PDC, RDC, SMDC are gradually maturing and are expected to break through ADC
The linker differences in different conjugation and targeting technologies are small, and they are classified according to their toxin molecules and targeted delivery molecules; ADC has strong targeting and relatively mature technology, but the antibody has a large molecular weight and it is difficult to break through solid tumors; RDC can achieve tumor Precise treatment; SMDCs are easy to penetrate into tumor tissues, but the development of ligands is extremely difficult.
Technical analysis : ADC technology has been developed to the third generation, and it is developing in the direction of higher efficiency, more precision and low toxicity
Up to now, the history of ADC research has been over a hundred years. The technology has also been replaced several times. So far, the ADC research and development process has reached the third stage of development. The first generation is represented by Pfizer’s Mylotarg, which has disadvantages such as low antigen specificity, strong toxicity/side effects, unstable linker, and short half-life; the second generation is represented by Seattle’s Adcetris and Roche’s Kadcyla. Compared with the first-generation ADC, the second-generation ADC has strong antigen specificity and higher efficacy. Low immunogenicity and other advantages, but there are still problems such as strong toxic and side effects, drug resistance, high DAR (drug-to-antbody ratio, drug loading rate of antibody) value; the third-generation third-generation ADC passes through the site Specific coupling, using a new target, can have a homogeneous single ADC, and the cytotoxic molecule is more effective, with higher precision and lower toxicity.
To view the full report please click
Note: Unless marked as original, all are contributions and sharing by netizens or institutions. If you have any publicity needs, please contact [email protected].
This article is transferred from: https://www.dx2025.com/archives/29115.html
This site is only for collection, and the copyright belongs to the original author.